322 related articles for article (PubMed ID: 34774454)
1. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed
Ophinni Y; Miki S; Hayashi Y; Kameoka M
Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
[TBL] [Abstract][Full Text] [Related]
4. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
6. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation.
Vergara-Mendoza M; Gomez-Quiroz LE; Miranda-Labra RU; Fuentes-Romero LL; Romero-Rodríguez DP; González-Ruiz J; Hernández-Rizo S; Viveros-Rogel M
Antiviral Res; 2020 Aug; 180():104856. PubMed ID: 32579898
[TBL] [Abstract][Full Text] [Related]
9. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
10. The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.
Darcis G; Binda CS; Klaver B; Herrera-Carrillo E; Berkhout B; Das AT
Viruses; 2019 Mar; 11(3):. PubMed ID: 30871200
[TBL] [Abstract][Full Text] [Related]
11. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
[TBL] [Abstract][Full Text] [Related]
12. Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.
Smith LM; Ladner JT; Hodara VL; Parodi LM; Harris RA; Callery JE; Lai Z; Zou Y; Raveedran M; Rogers J; Giavedoni LD
J Virol; 2021 Nov; 95(23):e0088221. PubMed ID: 34549979
[TBL] [Abstract][Full Text] [Related]
13. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
14. Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy.
Herskovitz J; Hasan M; Patel M; Kevadiya BD; Gendelman HE
Methods Mol Biol; 2022; 2407():429-445. PubMed ID: 34985679
[TBL] [Abstract][Full Text] [Related]
15. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
16. Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients.
Sullivan NT; Dampier W; Chung CH; Allen AG; Atkins A; Pirrone V; Homan G; Passic S; Williams J; Zhong W; Kercher K; Desimone M; Li L; C Antell G; Mell JC; Ehrlich GD; Szep Z; Jacobson JM; Nonnemacher MR; Wigdahl B
Sci Rep; 2019 Nov; 9(1):17088. PubMed ID: 31745112
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update.
Hashmat R; Yousaf MZ; Rahman Z; Anjum KM; Yaqoob A; Imran M
Crit Rev Eukaryot Gene Expr; 2020; 30(1):77-83. PubMed ID: 32421986
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA.
Binda CS; Klaver B; Berkhout B; Das AT
Viruses; 2020 Mar; 12(3):. PubMed ID: 32197474
[TBL] [Abstract][Full Text] [Related]
19. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
[TBL] [Abstract][Full Text] [Related]
20. Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9.
Yoder KE; Bundschuh R
Sci Rep; 2016 Jul; 6():29530. PubMed ID: 27404981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
